AU2022410066A1 - Nap for sex-specific treatment of diseases - Google Patents
Nap for sex-specific treatment of diseases Download PDFInfo
- Publication number
- AU2022410066A1 AU2022410066A1 AU2022410066A AU2022410066A AU2022410066A1 AU 2022410066 A1 AU2022410066 A1 AU 2022410066A1 AU 2022410066 A AU2022410066 A AU 2022410066A AU 2022410066 A AU2022410066 A AU 2022410066A AU 2022410066 A1 AU2022410066 A1 AU 2022410066A1
- Authority
- AU
- Australia
- Prior art keywords
- day
- pharmaceutical composition
- disease
- subject
- nap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289174P | 2021-12-14 | 2021-12-14 | |
| US63/289,174 | 2021-12-14 | ||
| US202263306146P | 2022-02-03 | 2022-02-03 | |
| US63/306,146 | 2022-02-03 | ||
| PCT/IL2022/051314 WO2023112025A1 (en) | 2021-12-14 | 2022-12-13 | Nap for sex-specific treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022410066A1 true AU2022410066A1 (en) | 2024-07-25 |
Family
ID=86773996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022410066A Pending AU2022410066A1 (en) | 2021-12-14 | 2022-12-13 | Nap for sex-specific treatment of diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250312408A1 (https=) |
| EP (1) | EP4447994A4 (https=) |
| JP (1) | JP2025501458A (https=) |
| KR (1) | KR20240135692A (https=) |
| AU (1) | AU2022410066A1 (https=) |
| CA (1) | CA3240138A1 (https=) |
| IL (1) | IL313226A (https=) |
| MX (1) | MX2024006777A (https=) |
| WO (1) | WO2023112025A1 (https=) |
-
2022
- 2022-12-13 WO PCT/IL2022/051314 patent/WO2023112025A1/en not_active Ceased
- 2022-12-13 AU AU2022410066A patent/AU2022410066A1/en active Pending
- 2022-12-13 CA CA3240138A patent/CA3240138A1/en active Pending
- 2022-12-13 IL IL313226A patent/IL313226A/en unknown
- 2022-12-13 EP EP22906851.5A patent/EP4447994A4/en active Pending
- 2022-12-13 MX MX2024006777A patent/MX2024006777A/es unknown
- 2022-12-13 JP JP2024533944A patent/JP2025501458A/ja active Pending
- 2022-12-13 US US18/718,925 patent/US20250312408A1/en active Pending
- 2022-12-13 KR KR1020247022758A patent/KR20240135692A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447994A1 (en) | 2024-10-23 |
| IL313226A (en) | 2024-07-01 |
| CA3240138A1 (en) | 2023-06-22 |
| WO2023112025A1 (en) | 2023-06-22 |
| MX2024006777A (es) | 2024-08-06 |
| KR20240135692A (ko) | 2024-09-11 |
| JP2025501458A (ja) | 2025-01-22 |
| US20250312408A1 (en) | 2025-10-09 |
| EP4447994A4 (en) | 2026-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hampel et al. | The amyloid-β pathway in Alzheimer’s disease | |
| Rahman et al. | Therapeutic implication of autophagy in neurodegenerative diseases | |
| Curcio-Morelli et al. | Macroautophagy is defective in mucolipin-1-deficient mouse neurons | |
| Solesio et al. | Carbonic anhydrase inhibition selectively prevents amyloid β neurovascular mitochondrial toxicity | |
| Harding et al. | Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities | |
| Menéndez | Down syndrome, Alzheimer's disease and seizures | |
| Vilchez et al. | The role of protein clearance mechanisms in organismal ageing and age-related diseases | |
| Hagerman | Lessons from fragile X regarding neurobiology, autism, and neurodegeneration | |
| Wang et al. | Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome | |
| Sharma et al. | Identification of LOXL1 protein and Apolipoprotein E as components of surgically isolated pseudoexfoliation material by direct mass spectrometry | |
| Zhang et al. | Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease | |
| Wang et al. | Calpain-2 as a therapeutic target for acute neuronal injury | |
| Tran et al. | Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer's disease | |
| Chu et al. | Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer’s disease | |
| US20180217163A1 (en) | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele | |
| Olsson et al. | Imatinib treatment and Aβ42 in humans | |
| Singulani et al. | Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium | |
| Straten et al. | Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease | |
| Liu et al. | Effect of ginkgolide K on calcium channel activity in Alzheimer's disease | |
| Ma et al. | Diabetes influences the fusion of autophagosomes with lysosomes in SH-SY5Y cells and induces Aβ deposition and cognitive dysfunction in STZ-induced diabetic rats | |
| Xiao | Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease | |
| US20250312408A1 (en) | Nap for sex-specific treatment of diseases | |
| Heredia et al. | Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid β precursor protein | |
| HK40117549A (zh) | 用於疾病的性别特异性治疗的nap | |
| Di Lucente et al. | The impact of mild episodic ketosis on microglia and hippocampal long‐term depression in 5xFAD mice |